hERG 스크리닝 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

hERG Screening Market - Scope of Report

TMR's report on the global hERG screening market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global hERG screening market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hERG screening market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the hERG screening market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hERG screening market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hERG screening market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hERG screening market.

The report delves into the competitive landscape of the global hERG screening market. Key players operating in the global hERG screening market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hERG screening market profiled in this report.

Key Questions Answered in Global hERG screening Market Report:

• What is the sales/revenue generated by hERG screening across all regions during the forecast period?
• What are the opportunities in the global hERG screening market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

hERG Screening Market - Research Objectives and Research Approach

The comprehensive report on the global hERG screening market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hERG screening market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hERG screening market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: hERG Screening Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. HERG Screening Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product /Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global hERG Screening Market Analysis and Forecast, by Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Type, 2020-2034
  • 6.3.1. Gene KCNH2
  • 6.3.2. Mutant KCNH2
• 6.4. Market Attractiveness Analysis, by Type

7. Global hERG Screening Market Analysis and Forecast, by Ion Channel

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Ion Channel, 2020-2034
  • 7.3.1. Voltage-Gated
  • 7.3.2. Ligand-Gated
• 7.4. Market Attractiveness Analysis, by Ion Channel

8. Global hERG Screening Market Analysis and Forecast, by Application

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Application, 2020-2034
  • 8.3.1. Antiarrhythmic
  • 8.3.2. Antipsychotic
  • 8.3.3. Antibiotics
  • 8.3.4. Others
• 8.4. Market Attractiveness Analysis, by Application

9. Global hERG Screening Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2020-2034
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America hERG Screening Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Type, 2020-2034
  • 10.3.1. Gene KCNH2
  • 10.3.2. Mutant KCNH2
• 10.4. Market Value Forecast, by Ion Channel, 2020-2034
  • 10.4.1. Voltage-Gated
  • 10.4.2. Ligand-Gated
• 10.5. Market Value Forecast, by Application, 2020-2034
  • 10.5.1. Antiarrhythmic
  • 10.5.2. Antipsychotic
  • 10.5.3. Antibiotics
  • 10.5.4. Others
• 10.6. Market Value Forecast, by Country, 2020-2034
  • 10.6.1. U.S.
  • 10.6.2. Canada
• 10.7. Market Attractiveness Analysis
  • 10.7.1. By Type
  • 10.7.2. By Ion Channel
  • 10.7.3. By Application
  • 10.7.4. By Country

11. Europe hERG Screening Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Type, 2020-2034
  • 11.3.1. Gene KCNH2
  • 11.3.2. Mutant KCNH2
• 11.4. Market Value Forecast, by Ion Channel, 2020-2034
  • 11.4.1. Voltage-Gated
  • 11.4.2. Ligand-Gated
• 11.5. Market Value Forecast, by Application, 2020-2034
  • 11.5.1. Antiarrhythmic
  • 11.5.2. Antipsychotic
  • 11.5.3. Antibiotics
  • 11.5.4. Others
• 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.6.1. Germany
  • 11.6.2. U.K.
  • 11.6.3. France
  • 11.6.4. Italy
  • 11.6.5. Spain
  • 11.6.6. Rest of Europe
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Type
  • 11.7.2. By Ion Channel
  • 11.7.3. By Application
  • 11.7.4. By Country/Sub-region

12. Asia Pacific hERG Screening Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Type, 2020-2034
  • 12.3.1. Gene KCNH2
  • 12.3.2. Mutant KCNH2
• 12.4. Market Value Forecast, by Ion Channel, 2020-2034
  • 12.4.1. Voltage-Gated
  • 12.4.2. Ligand-Gated
• 12.5. Market Value Forecast, by Application, 2020-2034
  • 12.5.1. Antiarrhythmic
  • 12.5.2. Antipsychotic
  • 12.5.3. Antibiotics
  • 12.5.4. Others
• 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.6.1. China
  • 12.6.2. Japan
  • 12.6.3. India
  • 12.6.4. Australia & New Zealand
  • 12.6.5. Rest of Asia Pacific
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Type
  • 12.7.2. By Ion Channel
  • 12.7.3. By Application
  • 12.7.4. By Country/Sub-region

13. Latin America hERG Screening Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Type, 2020-2034
  • 13.3.1. Gene KCNH2
  • 13.3.2. Mutant KCNH2
• 13.4. Market Value Forecast, by Ion Channel, 2020-2034
  • 13.4.1. Voltage-Gated
  • 13.4.2. Ligand-Gated
• 13.5. Market Value Forecast, by Application, 2020-2034
  • 13.5.1. Antiarrhythmic
  • 13.5.2. Antipsychotic
  • 13.5.3. Antibiotics
  • 13.5.4. Others
• 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.6.1. Brazil
  • 13.6.2. Mexico
  • 13.6.3. Rest of Latin America
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Type
  • 13.7.2. By Ion Channel
  • 13.7.3. By Application
  • 13.7.4. By Country/Sub-region

14. Middle East & Africa hERG Screening Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Type, 2020-2034
  • 14.3.1. Gene KCNH2
  • 14.3.2. Mutant KCNH2
• 14.4. Market Value Forecast, by Ion Channel, 2020-2034
  • 14.4.1. Voltage-Gated
  • 14.4.2. Ligand-Gated
• 14.5. Market Value Forecast, by Application, 2020-2034
  • 14.5.1. Antiarrhythmic
  • 14.5.2. Antipsychotic
  • 14.5.3. Antibiotics
  • 14.5.4. Others
• 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.6.1. GCC Countries
  • 14.6.2. South Africa
  • 14.6.3. Rest of Middle East & Africa
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Type
  • 14.7.2. By Ion Channel
  • 14.7.3. By Application
  • 14.7.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2023)
• 15.3. Company Profiles
  • 15.3.1. Abcam Limited
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. ABR-Affinity BioReagents, Inc.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. AstraZeneca plc
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Aureus Sciences
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. AVIVA Biosciences
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Cambridge Biosciences
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. ChanTest Corporation
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Charles River Laboratories
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. SWOT Analysis
    • 15.3.8.4. Financial Overview
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Chemaxon
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. SWOT Analysis
    • 15.3.9.4. Financial Overview
    • 15.3.9.5. Strategic Overview